Gefapixant 是一个 P2X3 受体拮抗剂，其对人同源重组 hP2X3 和 hP2X2/3 的 IC50值分别是约 30 和 100-250 nM。

Gefapixant is a P2X3 receptor (P2X3R) antagonist with IC50 of ~30 nM at recombinant hP2X3 homotrimers and 100-250 nM at hP2X2/3 heterotrimeric receptors.

The IC50 of Gefapixant has been reported as ~30 nM versus recombinant hP2X3 homotrimers and 100-250 nM at hP2X2/3 heterotrimeric receptors, potencies very similar to those reported for recombinant rat receptors, and it displays no inhibitory impact on any non-P2X3 subunit-containing receptors (IC50 values>>10,000 nM at recombinant homotrimeric hP2X1, hP2X2, hP2X4, rP2X5, and hP2X7 channels).

In a rat model of knee osteoarthritis (14d following intra-articular administration of monoiodoacetate), Gefapixant (7d bid, orally) attenuates the weight bearing laterality with a complete reversal of apparent hyperalgesia at the two higher doses [2].

A rodent model often employs for assessing the potential for drug effect in osteoarthritis (OA) pain is based on the intraarticular injection of monoiodoacetate (mIOA) into one knee joint of the rat. To measure the effect of Gefapixant on the weight bearing laterality and apparent hyperalgesia, Gefapixant is given by intraplantar or oral administration to the rats, with different concentrations (6, 20, and 60 mg/kg) two times a day and continues up to a week[2].

1015787-98-0

C14H19N5O4S

353.4

RO 4926219;MK-7264;AF219

H2O:Insoluble
DMSO:10 mM
Powder: -20°C for 3 years
In solvent: -80°C for 2 years